Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.

Shahrokh F ShariatKenichi HataShintaro NaritaShingo HatakeyamaKeiichiro MoriYuji YataTakayuki SanoTakashi OtsukaShuhei HaraKeiichiro MiyajimaYuki EneiWataru FukuokayaMinoru NakazonoAkihiro MatsukawaJun MikiTomonori HabuchiChikara OhyamaShahrokh F ShariatTakahiro Kimura

Published in: The Prostate (2023)

ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high-risk mHSPC. Compared to DOC, ABI resulted in longer time to CRPC but worse 2nd and 3rd-line PFS. Further studies are needed to clarify the optimal sequence of therapy in the upfront intensive treatment era.

Keyphrases

prostate cancer
radical prostatectomy
squamous cell carcinoma
small cell lung cancer
type diabetes
rectal cancer
replacement therapy
locally advanced
radiation therapy
metabolic syndrome
robot assisted
mesenchymal stem cells
bone marrow
weight loss
minimally invasive
case control
smoking cessation
glycemic control